drugset / Trial / NCT06092762
A Study to Evaluate the Safety and Efficacy of AK120 in Subjects With Moderate to Severe Atopic Dermatitis
RandomizedParallel-groupOpen-labelTreatment
Summary
This is a multicenter, randomized, open label phase II clinical study to evaluate the safety and efficacy of AK120 in the treatment of subjects with moderate to severe atopic dermatitis.
Timeline
- Start
- 2023-11-06
- Primary completion
- 2024-11-13
- Completion
- 2024-11-13
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | AK120 | Monoclonal antibody | 300 mg | Subcutaneous |
| Subject | AK120 | Monoclonal antibody | 450 mg | Subcutaneous |